Premium
Clinical Experiences in Oral Antidiabetic Therapy with Sulphonylureas and Biguanides
Author(s) -
Schöffling K.
Publication year - 1971
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1971.tb02575.x
Subject(s) - glibenclamide , tolbutamide , medicine , chlorpropamide , drug , potency , pharmacology , gliclazide , diabetes mellitus , endocrinology , biochemistry , chemistry , in vitro
Summary 1. Glibenclamide is a highly potent and nontoxic antidiabetic drug. 2. Many patients classified as secondary failures under tolbutamide have shown satisfactory results when given glibenclamide. However, it is still to be determined how long this improvement will last. 3. The three‐year study which has been reported gives evidence of the high potency and the efficacy of glibenclamide. 4. The use of sulphonylureas in combination with biguanides enlarges the group of diabetics who can be treated orally. At present, this combined treatment represents progress in oral therapy.